The trial’s primary efficacy endpoint was the proportion of subjects who achieved at least one stage of fibrosis improvement by week 26, without the worsening of MASH. Credit: Emily frost/Shutterstock.

Akero Therapeutics has revealed preliminary topline week 96 outcomes from its Phase IIb SYMMETRY study of efruxifermin (EFX) in individuals with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis (MASH).

The placebo-controlled, multicentre, double-blind, dose-ranging, randomised trial involved adult subjects with this condition.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Its primary efficacy endpoint was the proportion of subjects who achieved a minimum fibrosis improvement of one stage by week 36, without the worsening of MASH.

In subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage of the therapy experienced cirrhosis reversal without any worsening of MASH, compared to 15% in the placebo arm, the company noted.

In addition, 29% of subjects receiving the same dosage in the Intent to Treat (ITT) population, where missing week 96 biopsies were considered failures, showed cirrhosis reversal.

The effect size from week 36 to 96 in patients who received the 50mg dose more than doubled.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the patient subgroup not taking glucagon-like peptide 1 (GLP-1) at baseline, 45% in the 50mg EFX group reported cirrhosis reversal, compared to 17% for the placebo.

The most frequent adverse events across both EFX groups were gastrointestinal grade 1 or 2 events that were transient in nature.

Akero Therapeutics CEO and president Andrew Cheng  said: “We believe today’s first-ever public report of reversal of cirrhosis due to MASH, whether by completer or ITT analysis, sets EFX apart from other approved or investigational treatments in the MASH landscape as a compound with transformational potential.

“We look forward to continuing evaluation of 50mg EFX in our ongoing Phase III SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH.”

With the announcement of these promising results, Akero shares gained 117% in early trading, reported Reuters.